Jazz Pharma Revenue, Profits - JAZZ Annual Income Statement

Add to My Stocks
$164.36 $1.33 (0.82%) JAZZ stock closing price Sep 20, 2018 (Closing)

JAZZ stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Jazz Pharma stock price. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. Like any other income statement, the JAZZ income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a YOY revenue growth of 8.79% when compared to the same period in the past. The Jazz Pharma profit and loss statement for 2017 shows a net profit of $487.84M. Profits for last year was $396.83M. Apart from this an investor should also check Jazz Pharma assets and Jazz Pharma free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Jazz Pharma Revenues or Net Sales
1.62B1.49B1.32B1.17B872.42M585.97M272.27M173.78M128.44M67.51M
Cost Of Goods Sold (COGS)110.18M105.38M102.52M117.41M102.14M78.42M13.94M13.55M9.63M13.92M
Jazz Pharma Gross Profit
1.51B1.38B1.22B1.06B770.27M507.55M258.33M160.22M118.81M53.59M
Research & Development Expense283.44M186.04M135.25M287.8M46.62M20.47M14.12M25.61M36.56M69.96M
Selling General & Admin Expense544.15M604.88M480.64M445.47M304.3M223.88M108.93M68.99M58.65M141.16M
Income Before Depreciation Depletion Amortization680.9M591.65M606.38M322.17M419.35M263.19M135.27M65.61M23.59M-157.53M
Depreciation Depletion Amortization152.06M-98.16M126.58M79.04M65.35M7.44M7.82M7.66M12.82M
Non Operating Income-9.96M2.73M-15.37M8.68M-5.44M-3.62M-1.17M-12.28M-5.76M
Interest Expense77.75M61.94M56.91M52.71M26.91M16.86M1.67M12.72M22.79M19.74M
Jazz Pharma Pretax Income
441.11M532.44M435.93M151.55M307.95M177.35M124.98M32.77M-6.83M-184.33M
Provision for Income Taxes-47.74M135.23M106.39M94.23M91.63M-83.79M----
MinorityInterest----1.06M------
Investment Gains Losses-1M-0.37M--------
Other Income----------
Income Before Extraordinaries & Disc Operations487.84M396.83M329.53M57.32M216.31M261.14M124.98M32.77M-6.83M-184.33M
Extraordinary Items & Discontinued Operations-----27.43M----
Jazz Pharma Profit/ Loss (Net Income)
487.84M396.83M329.53M58.38M216.31M288.58M124.98M32.77M-6.83M-184.33M
Average Shares used to compute Diluted EPS61.32M61.87M63.04M62.61M61.57M60.2M46.8M39.41M30.02M25.65M
Average Shares used to compute Basic EPS60.02M60.5M61.23M59.75M58.3M56.64M41.5M36.34M30.02M25.65M
Income Before Nonrecurring Items585.68M396.83M530.9M463.55M343.71M267.39M144.18M47.89M-6.84M-154.58M
Income from Nonrecurring Items-97.83M--201.36M-405.16M-127.39M-6.24M-19.2M-15.11M--29.76M
Jazz Pharma Earnings Per Share Basic Net
8.136.565.380.983.715.093.010.90-0.23-7.19
Jazz Pharma Earnings Per Share Diluted Net
7.966.415.230.933.514.792.670.83-0.23-7.19
EPS Diluted Before Nonrecurring Items9.566.418.427.405.574.443.131.22-0.23-6.03
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Jazz Pharma stock analysis involves checking at least a few of the important things like:

  • Topline: A growing topline, as seen from the Jazz Pharma revenue chart, as is the case with Jazz Pharma indicates a growing business. One needs to compare the YoY topline or sales growth of JAZZ stock with its peers like NBIX stock and NKTR stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. JAZZ stock had a healthy bottom line growth.

The income statement is also called statement of revenue and expense. The JAZZ financials along with Jazz Pharma historical stock prices provide a lot of details about the firm.

Jazz Pharma Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
23.25
PS Ratio (price sales ratio)
5.52
Operating Margin
30.6
Net Profit Margin
18.4
Dividend Yield
0%